Disc Medicine posts smaller-than-expected Q2 net loss 

Overview

• US biopharma firm's Q2 net loss and operating income both beat analyst expectations

• Q2 loss per share was better than expected

• Operating expenses rose yr/yr due to pipeline advancement and higher headcount

Outlook

• Disc Medicine expects APOLLO Phase 3 topline results in Q4 2026

• Company anticipates submitting CRL response and receiving FDA decision by mid-2027

Result Drivers

• PIPELINE ADVANCEMENT - Co said higher RD expenses were driven by advancement of selcodebart and DISC-3405 clinical studies and drug manufacturing

• HEADCOUNT INCREASE - Co said higher SGA and RD expenses were partly due to increased headcount

• BITOPERTIN MANUFACTURING COSTS - Decrease in bitopertin manufacturing costs partially offset RD expense increases

Company press release: ID:nGNX4XH3s8

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology medical research peer group is "buy"

• Wall Street's median 12-month price target for Disc Medicine Inc is $100.00, about 35.7% above its July 29 closing price of $73.67

Reuters Recommended Reads

• July 30 - Crescent Biopharma posts smaller-than-expected Q2 net loss

• July 30 - Anavex Life Sciences Q2 net loss narrows on lower RD costs

• July 29 - Corcept Therapeutics Q2 revenue estimates, raises 2026 outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)